ReGen’s AGM statement confirms that the company’s cognitive enhancer Colostrinin is on track for a fourth-quarter 2007 launch. The company’s North American marketing partner, Metagenics, has confirmed that the important conditions of the firms’ agreement – including the completion of toxicology testing and validation of manufacturing facilities – have been satisfied. Metagenics is to commercialise the product as a nutraceutical through the professional channel, while the search for a mass market partner continues.

Unlock the rest of this article with a 14 day trial

or Unlock with your email

Already have an account?
Login here